This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01611272
First received: May 25, 2012
Last updated: July 11, 2017
Last verified: July 2017
May 25, 2012
July 11, 2017
April 30, 2013
July 20, 2016   (Final data collection date for primary outcome measure)
  • Number of Hemorrhage events [ Time Frame: up to 54 months ]
  • Number of other AEs [ Time Frame: up to 54 months ]
Same as current
Complete list of historical versions of study NCT01611272 on ClinicalTrials.gov Archive Site
  • Number of Stroke events [ Time Frame: up to 54 months ]
    for efficacy
  • Number of Cardiovascular (CV) related deaths events [ Time Frame: up to 54 months ]
    for efficacy
  • Number of Myocardial Infarction events [ Time Frame: up to 54 months ]
    for efficacy
Same as current
Not Provided
Not Provided
 
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status of occurrence of Adverse Events (AEs), the factors that may influence safety and efficacy of the drug.
A Post Marketing Surveillance to evaluate the safety and efficacy of Brilinta
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients who take Brilinta according to the local approval condition
Acute Coronary Syndromes
Not Provided
1
Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3402
July 20, 2016
July 20, 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with Acute Coronary Syndromes
  • Patients who are taking ticagrelor and ASA daily(75-150mg), or Patients who are taking ticagrelor only(In the case that the patients have contraindication with ASA. Contraindication should be recorded in accordance with local PI on CRFs)
  • Patients who have signed the Data release consent form prior to enrollment in this surveillance

Exclusion Criteria:

  • Patients with hypersensitivity to ingredients of this drug or with moderate or severe hepatic impairment or with medical history of intracranial hemorrhage
  • Patients with pathological hemorrhage at the time of administration
  • Patients being administrated strong CYP3A4 inhibitors
Sexes Eligible for Study: All
19 Years to 130 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01611272
D5130L00019
Not Provided
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Study Director: JooWon Lee AstraZeneca Korea
AstraZeneca
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP